Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motesanib plus Paclitaxel in HER2-negative Breast Cancer
NCT00356681Phase 2Terminated
- Sponsor
- Amgen
- Start
- Dec 2006
- Primary completion
- Feb 2009
01
Overview
Phase 2, randomised, double-blind trial of motesanib in breast cancer (3 arms), sponsored by Amgen. Primary endpoint: Objective Response Rate at 16 weeks. Started Dec 2006; status: terminated.
02
Drugs
motesanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00356681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356681.